<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Under pathophysiological conditions, alpha-amino-3-hydroxy-5-<z:chebi fb="36" ids="29309">methyl</z:chebi>-4-<z:chebi fb="0" ids="35595">isoxazole</z:chebi> <z:chebi fb="0" ids="17272">propionate</z:chebi> (AMPA) receptor activation is considered to play a key role in several disorders of the central <z:mp ids='MP_0008912'>nervous</z:mp> system </plain></SENT>
<SENT sid="1" pm="."><plain>In the search for AMPA receptor <z:chebi fb="68" ids="48706">antagonists</z:chebi>, the synthesis and pharmacological characterization of a series of novel compounds that are structurally related to GYKI 52466 (1), a well-known selective noncompetitive AMPA receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, was performed </plain></SENT>
<SENT sid="2" pm="."><plain>In vitro, 2,3-dimethyl-6-<z:chebi fb="1" ids="30396">phenyl</z:chebi>-12H-[1,3]dioxolo[4,5-h]imidazo[1,2-c][2,3]<z:chebi fb="13" ids="22720">benzodiazepine</z:chebi> (ZK 187638, 14a) antagonized the kainate-induced currents in cultured hippocampal neurons with an IC(50) of 3.4 microM in a noncompetitive fashion </plain></SENT>
<SENT sid="3" pm="."><plain>When tested in a clinically predictive rat model of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, this noncompetitive AMPA receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> significantly reduced <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e>, indicating that it is neuroprotective after permanent focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
</text></document>